Purpura
Therapeutic area
Hematology
Rare disease
No
- Definition
- A small blood vessel hemorrhage into the skin and/or mucous membranes. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Purpura
- Therapeutic area
- Hematology
- purpura
- purpura
- purpura (disease)
- All therapeutic areas
- Hematology
- Severity
- Mild
- MONDO ID
- MONDO:0002610
- Parent condition
- MONDO:0002243
Related records
Broader conditions (5)
- Disease
- Disease by body system or component
- Hematologic disorder
- Hemorrhagic disease
- Human disease
Narrower conditions (8)
- Acquired purpura fulminans
- Acquired thrombotic thrombocytopenic purpura
- Autoimmune thrombocytopenic purpura
- Congenital thrombotic thrombocytopenic purpura
- Hyperglobulinemic purpura
- Purpura fulminans
- Thrombocytopenic purpura
- Thrombotic thrombocytopenic purpura
Trials (495)
- " Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "
- "Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children"
- A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone
- A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
- A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
- A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
- A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
- A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia
- A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)
- A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)
- A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP
- A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia
- A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
- A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
- A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
- A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
- A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
- A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Drugs in development (1)
- Retinol Phase 2